Acute and late radiotherapy toxicity in patients with inflammatory bowel disease

Danny Y. Song, W. Thomas Lawrie, Ross A. Abrams, David R. Kafonek, Theodore M. Bayless, James S. Welsh, Theodore L. DeWeese

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the incidence of gastrointestinal complications in patients with inflammatory bowel disease (IBD) receiving radiotherapy (RT) and to identify possibly avoidable factors associated with these complications. Methods and Materials: Twenty-four patients were identified and their records reviewed; all had a history of IBD before receiving RT to fields encompassing some portion of the gastrointestinal tract (Crohn's disease) or to the abdomen or pelvis (ulcerative colitis or IBD not otherwise specified). Results: Five of 24 patients (21%) experienced Grade ≥3 acute gastrointestinal toxicity; all 5 received concurrent chemotherapy. Two of 24 patients (8%) experienced Grade ≥3 late gastrointestinal toxicity. There were no significant correlations between complications and IBD type, prior IBD-related surgery, use of medications for IBD, or status of IBD. Conclusion: Patients with IBD may have an increased risk for severe acute RT-related gastrointestinal complications that is more modest than generally perceived, because all patients who had Grade ≥3 acute complications in this study had received concurrent chemotherapy (p = 0.04). Further study is needed to assess this risk, as well as the impact of RT on these patients' future gastrointestinal morbidity.

Original languageEnglish (US)
Pages (from-to)455-459
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume51
Issue number2
DOIs
StatePublished - Oct 1 2001

Keywords

  • Crohn's disease
  • Inflammatory bowel
  • Radiation
  • Ulcerative colitis

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Acute and late radiotherapy toxicity in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this